We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018

Published: August 2018
Pages: 385
Code: F6EBBDCB8849B13B54F13C4399BAC740
Format: PDF
Publisher GBI Research
From Add to basket
$ 3,995.00
This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.
Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots.
Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.
Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.
Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca.

Additonal Information

  • - Which companies are the most active within the pipeline for pancreatic and bile duct cancer?
  • - Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • - What are the most important R&D milestones and data publications to have happened within this field?

Companies Mentioned

3-V Biosciences Inc
4P-Pharma SAS
4SC AG
AB Science SA
AbbVie Inc
AbGenomics International Inc
Ability Pharmaceuticals SL
Aclaris Therapeutics Inc
Actuate Therapeutics Inc
Adamed Sp z oo
Aduro BioTech Inc
Advantagene Inc
Advenchen Laboratories LLC
Agios Pharmaceuticals Inc
AGV Discovery SAS
AIMM Therapeutics BV
Alissa Pharma
Alligator Bioscience AB
Allinky Biopharma
Altor BioScience Corp
Ambrx Inc
amcure GmbH
Amgen Inc
Amplia Therapeutics Pty Ltd
Anavex Life Sciences Corp
Andarix Pharmaceuticals Inc
ANP Technologies Inc
AntiCancer Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
Aposense Ltd
Ariad Pharmaceuticals Inc
ARMO Biosciences Inc
ArQule Inc
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Axcentua Pharmaceuticals AB
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Berg LLC
BerGenBio ASA
Bexion Pharmaceuticals LLC
BeyondSpring Pharmaceuticals Inc
Bile Duct Cancer (Cholangiocarcinoma)
BioAtla LLC
BioLineRx Ltd
BioMoti Ltd
Biomunex Pharmaceuticals
Bionomics Ltd
BioNTech AG
Bio-Path Holdings Inc
Biothera Pharmaceutical Inc
Biouniversa srl
BLR Bio LLC
Boehringer Ingelheim GmbH
Boston Biomedical Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cancer Prevention Pharmaceuticals Inc
Cantargia AB
Cantex Pharmaceuticals Inc
CARsgen Therapeutics Ltd
CBT Pharmaceuticals Inc
CCRP Therapeutics GmbH
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celprogen Inc
Celyad SA
Centrose LLC
Chem-Master International Inc
ChemoCentryx Inc
Chugai Pharmaceutical Co Ltd
Clovis Oncology Inc
COARE Biotechnology Inc
Codiak BioSciences Inc
Concordia International Corp
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
CPL Biologicals Pvt Ltd
CrystalGenomics Inc
CTI BioPharma Corp
Cyclacel Pharmaceuticals Inc
CytImmune Sciences Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
CyTuVax BV
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Debiopharm International SA
DEKK-TEC Inc
Delcath Systems Inc
Denceptor Therapeutics Ltd
Diffusion Pharmaceuticals Inc
Eddingpharm Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Co
Endor Nanotechnologies SL
Ensol Biosciences Inc
Enterome Bioscience SA
Erytech Pharma SA
Esperance Pharmaceuticals Inc
Etubics Corp
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Felicitex Therapeutics Inc
FibroGen Inc
Formation Biologics Inc
Formosa Laboratories Inc
Forty Seven Inc
Fountain Biopharma Inc
Fujifilm Holdings Corporation
Fusion Antibodies Ltd
Galera Therapeutics Inc
GamaMabs Pharma SA
Geistlich Pharma AG
Genelux Corp
Genentech Inc
Genisphere LLC
Genmab A/S
Genoscience Pharma
Gilead Sciences Inc
GlaxoSmithKline Plc
GlycoMimetics Inc
Glycotope GmbH
Golden Biotechnology Corp
GW Pharmaceuticals Plc
H3 Biomedicine Inc
Halozyme Therapeutics Inc
Heidelberg Pharma AG
Helix BioPharma Corp
Hemispherx Biopharma Inc
Horizon Pharma Plc
Hutchison MediPharma Ltd
Icell Kealex Therapeutics LLC
Idera Pharmaceuticals Inc
Igenica Biotherapeutics Inc
Ignyta Inc
Immix BioPharma Inc
Immodulon Therapeutics Ltd
Immune System Key Ltd
Immunitor Inc
Immunomedics Inc
Immunotope Inc
Immunovo BV
Immupharma Plc
Incyte Corp
Inflection Biosciences Ltd
Innopharmax Inc
Innovation Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
InteRNA Technologies BV
Intezyne Technologies Inc
Inventiva
InvivoGen Therapeutics
Io Therapeutics Inc
Iovance Biotherapeutics Inc
Ipsen SA
ISU ABXIS Co Ltd
Jasco Pharmaceuticals LLC
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Kalyra Pharmaceuticals Inc
Karcinolys SAS
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Keystone Nano Inc
Komipharm International Co Ltd
Kringle Pharma Inc
Kuhnil Pharmaceutical Co Ltd
Kura Oncology Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Leap Therapeutics Inc
Lexicon Pharmaceuticals Inc
LIfT BioSciences Ltd
Lixte Biotechnology Holdings Inc
Loxo Oncology Inc
Lymphocyte Activation Technologies SA
MabVax Therapeutics Holdings Inc
Machavert Pharmaceuticals LLC
MacroGenics Inc
MaxiVAX SA
Meabco AS
Mebiopharm Co Ltd
MediaPharma SRL
Medicenna Therapeutics Corp
MediciNova Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
MetaMax Ltd
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Targeting Technologies Inc
Molecular Templates Inc
Moleculin Biotech LLC
Monopar Therapeutics Inc
Morphotek Inc
Mycenax Biotech Inc
NanoCarrier Co Ltd
NanoVector Inc
NantKwest Inc
Nascent Biotech Inc
Natco Pharma Ltd
NatureWise Biotech & Medicals Corp
NBE-Therapeutics AG
Nektar Therapeutics
Nerviano Medical Sciences Srl
NewLink Genetics Corp
NormOxys Inc
Northern Biologics Inc
Northwest Biotherapeutics Inc
Novartis AG
Noxxon Pharma AG
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Omeros Corp
Oncodesign SA
Oncology Research International Ltd
Oncolytics Biotech Inc
Oncomatryx Biopharma SL
OncoMed Pharmaceuticals Inc
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Oribase Pharma
Oryx GmbH & Co KG
OSE Immunotherapeutics
Oxford BioTherapeutics Ltd
Patrys Ltd
PCI Biotech Holding ASA
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaCyte Biotech Inc
Pharmedartis GmbH
Phenex Pharmaceuticals AG
Phoenix Biotechnology Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
POP Biotechnologies Inc
Precision Biologics Inc
Prescient Therapeutics Ltd
Propanc Biopharma Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
Puma Biotechnology Inc
Purdue Pharma LP
Puretech Health plc
Quest PharmaTech Inc
Quimatryx SL
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Rexahn Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
RS Research
Sagetis Biotech SL
Samumed LLC
Samyang Holdings Corp
Sanofi
Sareum Holdings Plc
SATT North SAS
Scancell Holdings Plc
Seattle Genetics Inc
Selecta Biosciences Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Sensei Biotherapeutics Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Siamab Therapeutics Inc
Sichuan Kelun Pharmaceutical Co Ltd
Sierra Oncology Inc
SignalChem Lifesciences Corp
SignPath Pharma Inc
SilaGene Inc
Silenseed Ltd
Sillajen Biotherapeutics
Sino Biopharmaceutical Ltd
Sirnaomics Inc
Soricimed Biopharma Inc
Spring Bank Pharmaceuticals Inc
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co Ltd
Sun BioPharma Inc
Sun Pharma Advanced Research Company Ltd
Swedish Orphan Biovitrum AB
Symic Biomedical Inc
Symphogen A/S
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
Synergys Biotherapeutics Inc
Synovo GmbH
SyntheX Inc
Taiho Pharmaceutical Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Takis Srl
Targovax ASA
Taris Biomedical LLC
Tarveda Therapeutics Inc
TCR2 Therapeutics Inc
tella Inc
Tesaro Inc
Tiziana Life Sciences Plc
Tocagen Inc
Transcriptogen Ltd
Transgene SA
Trovagene Inc
Tyg Oncology Ltd
Tyme Technologies Inc
Tyrogenex Inc
UbiVac LLC
ValiRx Plc
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxeal Holding SA
Vaximm AG
Vaxon Biotech
VCN Biosciences SL
Vect-Horus SAS
Verastem Inc
VG Life Sciences Inc
Vicus Therapeutics LLC
Viralytics Ltd
Virobay Inc
ViroStatics srl
XBiotech Inc
XuanZhu Pharma Co Ltd
Zeria Pharmaceutical Co Ltd

Reasons to buy

Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Add to basket
  • 1 Table of Contents
  • 1 Table of Contents 4
  • 1.1 List of Tables 5
  • 1.2 List of Figures 13
  • 2 Introduction 14
  • 2.1 Pancreatic and Bile Duct Cancer Report Coverage 14
  • 2.2 Pancreatic Cancer - Overview 14
  • 2.3 Bile Duct Cancer (Cholangiocarcinoma) - Overview 14
  • 3 Therapeutics Development 15
  • 3.1 Pancreatic Cancer 15
  • 3.2 Bile Duct Cancer (Cholangiocarcinoma) 67
  • 4 Therapeutics Assessment 81
  • 4.1 Pancreatic Cancer 81
  • 4.2 Bile Duct Cancer (Cholangiocarcinoma) 113
  • 5 Companies Involved in Therapeutics Development 125
  • 5.1 Pancreatic Cancer 125
  • 5.2 Bile Duct Cancer (Cholangiocarcinoma) 287
  • 6 Dormant Projects 328
  • 6.1 Pancreatic Cancer 328
  • 6.2 Bile Duct Cancer (Cholangiocarcinoma) 344
  • 7 Discontinued Products 347
  • 7.1 Pancreatic Cancer 347
  • 7.2 Bile Duct Cancer (Cholangiocarcinoma) 351
  • 8 Product Development Milestones 352
  • 8.1 Pancreatic Cancer 352
  • 8.2 Bile Duct Cancer (Cholangiocarcinoma) 369
  • 9 Appendix 384
  • 9.1 Methodology 384
  • 9.2 Coverage 384
  • 9.3 Secondary Research 384
  • 9.4 Primary Research 384
  • 9.5 Expert Panel Validation 384
  • 9.6 Contact Us 385
  • 9.7 Disclaimer 385
  • 1.1 List of Tables
  • Table 1: Number of Products under Development for Pancreatic Cancer 15
  • Table 2: Number of Products under Development by Companies, Pancreatic Cancer 17
  • Table 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 30
  • Table 4: Products under Development by Companies, Pancreatic Cancer 32
  • Table 5: Products under Development by Universities/Institutes, Pancreatic Cancer 62
  • Table 6: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67
  • Table 7: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 69
  • Table 8: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72
  • Table 9: Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 73
  • Table 10: Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 80
  • Table 11: Number of Products by Stage and Target, Pancreatic Cancer 82
  • Table 12: Number of Products by Stage and Mechanism of Action, Pancreatic Cancer 94
  • Table 13: Number of Products by Stage and Route of Administration, Pancreatic Cancer 110
  • Table 14: Number of Products by Stage and Molecule Type, Pancreatic Cancer 112
  • Table 15: Number of Products by Stage and Target, Bile Duct Cancer (Cholangiocarcinoma) 114
  • Table 16: Number of Products by Stage and Mechanism of Action, Bile Duct Cancer (Cholangiocarcinoma) 118
  • Table 17: Number of Products by Stage and Route of Administration, Bile Duct Cancer (Cholangiocarcinoma) 122
  • Table 18: Number of Products by Stage and Molecule Type, Bile Duct Cancer (Cholangiocarcinoma) 124
  • Table 19: Pancreatic Cancer - Pipeline by 3-V Biosciences Inc 125
  • Table 20: Pancreatic Cancer - Pipeline by 4P-Pharma SAS 125
  • Table 21: Pancreatic Cancer - Pipeline by 4SC AG 126
  • Table 22: Pancreatic Cancer - Pipeline by AB Science SA 126
  • Table 23: Pancreatic Cancer - Pipeline by AbbVie Inc 127
  • Table 24: Pancreatic Cancer - Pipeline by AbGenomics International Inc 128
  • Table 25: Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL 128
  • Table 26: Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc 128
  • Table 27: Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc 129
  • Table 28: Pancreatic Cancer - Pipeline by Adamed Sp z oo 129
  • Table 29: Pancreatic Cancer - Pipeline by Aduro BioTech Inc 130
  • Table 30: Pancreatic Cancer - Pipeline by Advantagene Inc 130
  • Table 31: Pancreatic Cancer - Pipeline by AGV Discovery SAS 131
  • Table 32: Pancreatic Cancer - Pipeline by AIMM Therapeutics BV 131
  • Table 33: Pancreatic Cancer - Pipeline by Alissa Pharma 132
  • Table 34: Pancreatic Cancer - Pipeline by Alligator Bioscience AB 132
  • Table 35: Pancreatic Cancer - Pipeline by Allinky Biopharma 132
  • Table 36: Pancreatic Cancer - Pipeline by Altor BioScience Corp 133
  • Table 37: Pancreatic Cancer - Pipeline by Ambrx Inc 133
  • Table 38: Pancreatic Cancer - Pipeline by amcure GmbH 134
  • Table 39: Pancreatic Cancer - Pipeline by Amgen Inc 134
  • Table 40: Pancreatic Cancer - Pipeline by Amplia Therapeutics Pty Ltd 135
  • Table 41: Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp 135
  • Table 42: Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc 136
  • Table 43: Pancreatic Cancer - Pipeline by ANP Technologies Inc 136
  • Table 44: Pancreatic Cancer - Pipeline by AntiCancer Inc 136
  • Table 45: Pancreatic Cancer - Pipeline by APEIRON Biologics AG 137
  • Table 46: Pancreatic Cancer - Pipeline by Apexigen Inc 137
  • Table 47: Pancreatic Cancer - Pipeline by Aphios Corp 138
  • Table 48: Pancreatic Cancer - Pipeline by Aposense Ltd 138
  • Table 49: Pancreatic Cancer - Pipeline by ARMO Biosciences Inc 139
  • Table 50: Pancreatic Cancer - Pipeline by ArQule Inc 139
  • 1.2 List of Figures
  • Figure 1: Number of Products under Development for Pancreatic Cancer 15
  • Figure 2: Number of Products under Development by Companies, Pancreatic Cancer 16
  • Figure 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 29
  • Figure 4: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67
  • Figure 5: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 68
  • Figure 6: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72
  • Figure 7: Number of Products by Top 10 Targets, Pancreatic Cancer 81
  • Figure 8: Number of Products by Stage and Top 10 Targets, Pancreatic Cancer 81
  • Figure 9: Number of Products by Top 10 Mechanism of Actions, Pancreatic Cancer 93
  • Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Pancreatic Cancer 93
  • Figure 11: Number of Products by Top 10 Routes of Administration, Pancreatic Cancer 109
  • Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Pancreatic Cancer 109
  • Figure 13: Number of Products by Top 10 Molecule Types, Pancreatic Cancer 111
  • Figure 14: Number of Products by Stage and Top 10 Molecule Types, Pancreatic Cancer 111
  • Figure 15: Number of Products by Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113
  • Figure 16: Number of Products by Stage and Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113
  • Figure 17: Number of Products by Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117
  • Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117
  • Figure 19: Number of Products by Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121
  • Figure 20: Number of Products by Stage and Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121
  • Figure 21: Number of Products by Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123
  • Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123

;